Compare Tango Therapeutics Inc. (TNGX) vs Upstart Holdings Inc (UPST) Price & Performance

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.

Upstart Holdings trades at $23.83, showing modest daily gains of 0.34% but remains in a bearish technical trend. The company reported mixed Q2 2026 earnings with $0.16 EPS missing expectations of $0.18, though revenue growth accelerated to $1.02 billion in 2025 with positive net income of $54 million. Recent news highlights partnership expansions into HELOC and auto lending while the stock faces pressure near 52-week lows.

Despite recent profitability improvements, Upstart faces execution risks with three consecutive earnings misses and negative operating cash flow. Analyst consensus remains divided with a $38.13 price target suggesting 60% upside potential, but high valuation multiples and competitive pressures in consumer lending warrant caution for investors.